Statins significantly reduce mortality in patients receiving clopidogrel without affecting platelet activation and aggregation: a systematic review and meta-analysis

BackgroundCombination of statins and clopidogrel is frequently administered in patients with coronary artery disease (CAD). They are mainly activated and eliminated in the liver by cytochrome P450 isoenzyme 3A4 (CYP3A4). The aim was to clarify whether the coadministration of clopidogrel and statins attenuate respective efficacy.MethodsPubMed, Embase, the Cochrane Library, Web of Science and Clinical Trials. gov were searched for until August 2018. Randomized controlled trials (RCTs) and cohort studies were taken into quality evaluation. Data were pooled using random effect models to estimate standard mean difference (SMD) or risk ratio (RR) with 95% confidence interval (CI).ResultsIn total, 28 studies representing 25,267 participants were included. Statins reduce the mortality of patients administered clopidogrel (RR 0.54; 95% CI 0.40,0.74; p=0.000), no differences were found in platelet aggregation (PA) (SMD 0.02; 95% CI -0.38,0.42; p=0.920) and the expressions of P-selectin (SMD -0.04; 95% CI -0.14,0.05; p=0.346), CD40L (SMD 0.09; 95% CI -0.29,0.48; p=0.633), CD63 (SMD 0.09; 95% CI -0.01,0.19; p=0.079) and PAC-1 (SMD 0.03; 95% CI -0.08,0.13; p=0.633). Furthermore, CYP3A4 metabolized or non-CYP3A4 metabolized statins have no discrepancies in PA (SMD 0.13; 95% CI -0.31,0.58; p=0.556), P-selectin (SMD 0.17; 95% CI -0.16,0.51; p=0310), death (RR 0.89; 95% CI 0.38,2.07; p=0.791), except for triglyceride (TG) (SMD -0.19; 95% CI -0.33,-0.06; p=0.005).ConclusionsThis meta-analysis confirmed that statins reduce mortality in patients undergoing clopidogrel treatment without affecting platelet activation and aggregation.